Track topics on Twitter Track topics that are important to you
ZURICH (Reuters) - Novartis's investigational medicine canakinumab cut cardiovascular risk for people who had survived a heart attack, the Swiss drugmaker said on Thursday, citing a late-stage study.
Original Article: Novartis's canakinumab cut risks for heart attack survivors: studyNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Acute Coronary Syndromes ACS
Acute Coronary Syndromes (ACS) is an umbrella term for situations where the blood supplied to the heart muscle is suddenly blocked. Treatment for acute coronary syndrome includes medicines and a procedure known as angioplasty, during which doctors inflat...